Bladder cancer drug combo trial stalls early
NCT ID NCT01382706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small phase II study tested whether combining the chemotherapy drug docetaxel with the targeted therapy lapatinib could help patients with advanced bladder cancer that had already been treated with platinum-based chemo. Only 15 people enrolled before the study was terminated early, so we have very little data on how well it worked or what side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- docetaxel and lapatinib
- What this could lead to
- If successful, this combination could offer a second-line treatment option for advanced bladder cancer patients who have already tried platinum-based chemotherapy.
- What could go wrong
- The trial was terminated early with only 15 participants, so results are very limited. It is unclear if the combination is effective or safe enough to pursue further.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.